BioWorld MedTech

April 20, 2016

JNJ kicks off 2016 with strong Q1, but device biz may get a Band-Aid

Johnson & Johnson(J&J) reported a strong first quarter overall, beating quarterly earnings forecasts on prescription drug revenue, but the company's medical device business has seen better days. Read More

The new kid on China's block, ophthalmology market enjoys boom

Ontario startup offers pragmatic tool for low cost hip replacement

CMS skeptical about new tech add-on for Edwards Intuity valve

Other news to note

Financings

Product Briefs

Keeping you up to date on recent developments in oncology

Today's news in brief

BioWorld

BioWorld briefs for Feb. 14, 2025.

European VCs optimistic for med-tech exit opportunities in 2025

BioWorld MedTech

To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for February 14, 2025

European VCs bullish on med-tech investments in 2025

BioWorld MedTech

European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...

3D illustration of acute myeloid leukemia cells

Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML

BioWorld

Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...